Ekta Bagri

1 month ago | finance.yahoo.com | Ekta Bagri

Last week, biotech bigwig Gilead Sciences, Inc. GILD reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny. In the year-ago quarter, the company reported a loss per share of $1.32. Total revenues of $6.7 billion also missed the Zacks Consensus Estimate of $6.8 billion. Revenues were roughly flat year over year as lower Veklury (remdesivir) and oncology sales were offset by higher HIV and Liver Disease sales.

1 month ago | finance.yahoo.com | Ekta Bagri

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Ekta Bagri Mon, Apr 28, 2025, 6:18 AM 6 min read Last week, Bristol Myers BMY reported better-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.80 comfortably beat the Zacks Consensus Estimate of $1.51. In the year-ago quarter, BMY posted an adjusted loss per share of $4.40. Total revenues of $11.2 billion surpassed the Zacks Consensus Estimate of $10.7 billion.

2 months ago | zacks.com | Ekta Bagri

Shares of AC Immune ( - Free Report) have lost 18.3% in the past month compared with the industry’s decline of 1.3%. The stock has underperformed the sector and the S&P 500 Index during this timeframe. Earlier in the month, ACIU reported better-than-expected results for the fourth quarter. Nonetheless, shares of this Switzerland-based clinical-stage biopharmaceutical company continue to slide down.

2 months ago | zacks.com | Ekta Bagri

Shares of Pacira BioSciences ( - Free Report) have surged 66.8% in the past six months against the industry’s decline of 8.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe. Strong quarterly results, consistent growth in sales of lead drug Exparel and encouraging pipeline progress have boosted investor sentiment.

2 months ago | zacks.com | Ekta Bagri

Shares of Harmony Biosciences ( - Free Report) have lost 10.8% in the past six months compared with the industry’s decline of 9.7%. The stock has also underperformed the S&P 500 index during this timeframe. The stock was hit last month after the company announced that it received a Refusal to File (RTF) letter from the FDA for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH).